<DOC>
	<DOCNO>NCT01305369</DOCNO>
	<brief_summary>Cysteinyl leukotrienes ( cys-LTs ) lipid inflammatory mediator abound mucosal inflammation play validate role pathogenesis human asthma . It recently demonstrate platelet adenosine diphosphate ( ADP ) receptor , P2Y12 , require LT4-mediated pulmonary inflammation could novel potential therapeutic target asthma . Thienopyridines ( ticlopidine clopidogrel ) pro-drugs , proven antithrombotic efficacy , whose active metabolite selectively inhibit platelet P2Y12 receptor . One drawbacks thienopyridines high inter-individual variability pharmacological response , mostly due high inter-individual variability capacity transform pro-drug active metabolite . Prasugrel new member class thienopyridines , fast onset action uniform inhibition platelet function compare thienopyridines . Primary objective study test whether inhibition platelet P2Y12 receptor prasugrel reduce bronchial hyper-reactivity patient chronic asthma . The investigator design randomize , double blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) , crossover , placebo-controlled , prospective study , enroll 26 patient . Randomization perform sequential block . Patients blindly randomly allocate treatment A ( prasugrel 10 mg daily ) B ( placebo ) 15 day . After 15-day wash-out period , patient initially allocate treatment `` A '' allocate treatment `` B '' , vice versa . Measurements do baseline day 15 treatment , time ( +/- 1 h ) day . Primary efficacy measure change airway hyper-responsiveness , record reduction FEV1 use mannitol test induction . Secondary efficacy measure change marker airway inflammation sputum , change measurement nitric oxide expiration ( surrogate marker airway lung inflammation ) , count eosinophil granulocytes peripheral blood smear , change asthma exacerbation rate symptom score . Changes phosphorylation platelet VASP ( Vasodilator-stimulated phosphoprotein ) ADP , measure flow cytometric technique , use marker degree inhibition platelet P2Y12 receptor attain subject treatment prasugrel .</brief_summary>
	<brief_title>The Effect Prasugrel Bronchial Hyperreactivity Markers Inflammation Patients With Chronic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Bronchial Hyperreactivity</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Patients chronic asthma , diagnose base occurrence episodic wheezing , chest tightness and/or dyspnoea objectively confirm accord standard criterion , methacholine airway hyperresponsiveness ( PC20 FEV1 &lt; 16mg/ml ) positivity skin test common allergen ( prick test ) Positivity bronchial challenge test mannitol Age range 1874 year old Duration asthma &gt; 1 year Mild stable asthma without chronic medication , except use inhale low dose steroid use inhaled beta2agonist demand Written inform consent Pregnancy/lactation Active bleeding high risk bleed contraindicate treatment antiplatelet agent anticoagulants Previous TIA stroke Age â‰¥ 75 year old Other indication antiplatelet therapy Systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg Body weight &lt; 60 Kg Use FANS last 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>ASTHMA</keyword>
	<keyword>PLATELET RECEPTOR P2Y12</keyword>
	<keyword>PRASUGREL</keyword>
	<keyword>INFLAMMATION</keyword>
</DOC>